[go: up one dir, main page]

PE20000173A1 - DERIVATIVES OF PIPERACIN AS ANTAGONISTS OF NEUROQUININ - Google Patents

DERIVATIVES OF PIPERACIN AS ANTAGONISTS OF NEUROQUININ

Info

Publication number
PE20000173A1
PE20000173A1 PE1999000021A PE00002199A PE20000173A1 PE 20000173 A1 PE20000173 A1 PE 20000173A1 PE 1999000021 A PE1999000021 A PE 1999000021A PE 00002199 A PE00002199 A PE 00002199A PE 20000173 A1 PE20000173 A1 PE 20000173A1
Authority
PE
Peru
Prior art keywords
alkyl
ora
neuroquinin
heteroaryl
group
Prior art date
Application number
PE1999000021A
Other languages
Spanish (es)
Inventor
Ho-Jane Shue
Neng-Yang Shih
David J Blythin
John J Piwinski
Kevin D Mccormick
Xiao Chen
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp filed Critical Schering Corp
Publication of PE20000173A1 publication Critical patent/PE20000173A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/08—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/14—Antitussive agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/08—Bridged systems
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/582—Recycling of unreacted starting or intermediate materials

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

SE REFIERE A COMPUESTOS I, X ES O, NRd o S; n, u Y l SON 0-2; m ES 1, E y ES 1-3; m ES 2 E y ES 0; Rc ES H, ALQUILO C1-C6, -(CH2)n1-R4; n1 ES 1-6; Rd ES H, ALQUILO C1-C6, CN, ORa, ENTRE OTROS; R4 ES -ORa, SRa, -CN, -N(-Ra)(-Rb), -C(=O)-N(-Ra)(-Rb), ENTRE OTROS; Rc` ES H, ALQUILO C1-C6, (CH2)nORa, SOLO UN Rc o Rc' NO ES H; CADA Ra Y Rb ES H, ALQUILO C1-C6, FENILO, BENCILO, ALILO; CUANDO R4 ES -N-(-Rb)-C(=O)-ORa; Ra NO ES H; O CUANDO Ra Y Rb SE UNEN AL N Y FORMAN UN ANILLO DE 4 A 7 MIEMBROS; CADA R1 Y R2 ES H, ALQUILO C1-C6, CF3, C2F5, ENTRE OTROS; Ra NO ES H EN -S(=O)-Ra, -S(=O)(=O)-Ra, -N(-Rb)-C(=O)-ORa; O CUANDO R1 Y R2 FORMAN UN GRUPO b; n' ES 1 o 2; CADA R3 ES H, ALQUILO C1-C6, CF3, ENTRE OTROS; Ar1 ES HETEROARILO DE FORMULA c, Q ES N o CH; Ar2 ES HETEROARILO DE FORMULA d; Z ES UN GRUPO e; m1 ES 0-1; m2 ES 1-2; n3 ES 0-4; CADA Re Y Rf SON H, ALQUILO C1-C6, FENILO, BENCILO, ALILO, o Re Y Rf FORMAN UN CARBONILO EN EL GRUPO f; n5 ES 1-2; R5 ES H, ALQUILO C1-C6, (CH2)n1-R4, ENTRE OTROS, R6 ES H, ALQUILO C1-C6, ENTRE OTROS; CUANDO X3 ES H, O, NRd o S; R6 ES HETEROARILO, HETEROCICLOALQUILO, CUANDO n3 ES 0-4. EL COMPUESTO I ES ANTAGONISTA DEL RECEPTOR NEUROQUININA (NK), DE PREFERENCIA NK1 Y PUEDE SER UTIL EN EL TRATAMIENTO DE ASMA, ANSIEDAD, DEPRESION, EMESIS, TRASTORNO DE LA PIEL, TOSREFERS TO COMPOUNDS I, X IS O, NRd or S; n, u AND l ARE 0-2; m ES 1, E and ES 1-3; m ES 2 E and ES 0; Rc IS H, C1-C6 ALKYL, - (CH2) n1-R4; n1 IS 1-6; Rd IS H, C1-C6 ALKYL, CN, ORa, AMONG OTHERS; R4 IS -ORa, SRa, -CN, -N (-Ra) (-Rb), -C (= O) -N (-Ra) (-Rb), AMONG OTHERS; Rc` IS H, C1-C6 ALKYL, (CH2) nORa, ONLY ONE Rc or Rc 'IS NOT H; EACH Ra AND Rb IS H, C1-C6 ALKYL, PHENYL, BENZYL, ALLYL; WHEN R4 IS -N - (- Rb) -C (= O) -ORa; Ra IS NOT H; OR WHEN Ra AND Rb JOIN THE N AND FORM A RING OF 4 TO 7 MEMBERS; EACH R1 AND R2 IS H, C1-C6 ALKYL, CF3, C2F5, AMONG OTHERS; Ra IS NOT H IN -S (= O) -Ra, -S (= O) (= O) -Ra, -N (-Rb) -C (= O) -ORa; OR WHEN R1 AND R2 ARE A GROUP b; n 'IS 1 or 2; EACH R3 IS H, C1-C6 ALKYL, CF3, AMONG OTHERS; Ar1 IS HETEROARYL OF FORMULA c, Q IS N or CH; Ar2 IS HETEROARYL OF FORMULA d; Z IS A GROUP e; m1 IS 0-1; m2 IS 1-2; n3 IS 0-4; EACH Re AND Rf ARE H, C1-C6 ALKYL, PHENYL, BENZYL, ALLYL, or Re AND Rf FORM A CARBONYL IN GROUP f; n5 IS 1-2; R5 IS H, C1-C6 ALKYL, (CH2) n1-R4, AMONG OTHERS, R6 IS H, C1-C6 ALKYL, AMONG OTHERS; WHEN X3 IS H, O, NRd, or S; R6 IS HETEROARYL, HETEROCYCLOALKYL, WHEN n3 IS 0-4. COMPOUND I IS ANTAGONIST OF THE NEUROQUININ RECEPTOR (NK), OF PREFERENCE NK1 AND MAY BE USEFUL IN THE TREATMENT OF ASTHMA, ANXIETY, DEPRESSION, EMESIS, SKIN DISORDER, COUGH

PE1999000021A 1998-01-14 1999-01-11 DERIVATIVES OF PIPERACIN AS ANTAGONISTS OF NEUROQUININ PE20000173A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US694298A 1998-01-14 1998-01-14

Publications (1)

Publication Number Publication Date
PE20000173A1 true PE20000173A1 (en) 2000-03-09

Family

ID=21723387

Family Applications (1)

Application Number Title Priority Date Filing Date
PE1999000021A PE20000173A1 (en) 1998-01-14 1999-01-11 DERIVATIVES OF PIPERACIN AS ANTAGONISTS OF NEUROQUININ

Country Status (10)

Country Link
EP (1) EP1047698A1 (en)
JP (1) JP2002509151A (en)
CN (1) CN1135232C (en)
AR (1) AR014950A1 (en)
AU (1) AU2101399A (en)
CA (1) CA2317760A1 (en)
CO (1) CO5080777A1 (en)
PE (1) PE20000173A1 (en)
WO (1) WO1999036424A1 (en)
ZA (1) ZA99171B (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2649996A1 (en) 2006-04-26 2007-11-08 Merck Sharp & Dohme Limited Piperidines and related compounds for treatment of alzheimer's disease
AU2008208920A1 (en) 2007-01-24 2008-07-31 Glaxo Group Limited Pharmaceutical compositions comprising 3, 5-diamin0-6- (2, 3-dichl0phenyl) -l, 2, 4-triazine or R(-) -2, 4-diamino-5- (2, 3-dichlorophenyl) -6-fluoromethyl pyrimidine and an NK1
EP3072891A1 (en) * 2015-03-24 2016-09-28 Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. New Toll-Like Receptor 9 Antagonists

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR9610277A (en) * 1995-08-31 1999-07-06 Schering Corp Piperazine derivatives as neurowuinin antagonists
ATE325118T1 (en) * 1996-10-30 2006-06-15 Schering Corp PIPERAZINO DERIVATIVES AS NEUROKININ ANTAGONISTS

Also Published As

Publication number Publication date
CN1135232C (en) 2004-01-21
AR014950A1 (en) 2001-04-11
CO5080777A1 (en) 2001-09-25
ZA99171B (en) 1999-07-12
JP2002509151A (en) 2002-03-26
EP1047698A1 (en) 2000-11-02
CA2317760A1 (en) 1999-07-22
WO1999036424A1 (en) 1999-07-22
AU2101399A (en) 1999-08-02
CN1305481A (en) 2001-07-25

Similar Documents

Publication Publication Date Title
FI901739A0 (en) BENSIMIDAZOLER, DESSA FOERENINGAR INNEHAOLLANDE CEILING MODEL OCH FOERFARANDE FOER DERAS FRAMSTAELLNING.
PE20020332A1 (en) DERIVATIVES OF 4-PHENYL-PYRIDINE AS ANTAGONISTS OF NEUROQUININ NK-1 RECEPTORS
ATE469892T1 (en) SUBSTITUTED 1H-DIHYDROPYRAZOLES, THEIR PREPARATION AND USE
ATE277602T1 (en) PHARMACEUTICAL COMPOSITIONS OF HETEROCYCLIC ANGIOTENSIN-II ANTAGONISTS AND OILY SUBSTANCES FOR ORAL ADMINISTRATION AND METHOD OF PRODUCTION THEREOF
TR199901674T2 (en)
DE69114614D1 (en) Polyethylene glycol derivatives, modified peptides thereof, their preparation and use of the modified peptides.
AR004516A1 (en) DERIVATIVES OF PYRIMIDINE, ITS USE, PROCEDURES TO PREPARE THEM AND MEDICINES THAT CONTAIN THEM
PE20011035A1 (en) CYCLIC UREAS SUBSTITUTED AS ANTAGONISTS OF NEUROQUININ RECEPTORS
ATE249843T1 (en) DELTA 1.6 BICYCLO (4,4,0) BASED DYES FOR CONTRAST ENHANCEMENT IN OPTICAL IMAGING
PE20010854A1 (en) USE OF SUBSTITUTED PYRIMIDINE 4 DERIVATIVES AS ANTAGONISTS OF GLUTAMATE mGluR1 RECEPTORS
ATE126517T1 (en) USE OF BIS(3,4-DIALKYLBENZYLIDENE)SORBITOLACETALS AND COMPOSITIONS CONTAINING SAME.
ES2057076T3 (en) QUINOXALINE COMPOUNDS AND THEIR PREPARATION AND USE.
CA2324418A1 (en) Novel opiate compounds, methods of making and methods of use
AR037926A1 (en) POLYMERS FOR CLEANING COMPOSITIONS FOR CLOTHING WASHING
NZ528997A (en) Sulfonamides
ATE367815T1 (en) USE OF A VASOPRESSIN ANTAGONIST SUCH AS CONIVAPTAN TO PRODUCE A MEDICATION FOR THE TREATMENT OF PULMONARY HYPERTENSION
PE20000173A1 (en) DERIVATIVES OF PIPERACIN AS ANTAGONISTS OF NEUROQUININ
ATE181552T1 (en) ISATINOXIM DERIVATIVES, THEIR PRODUCTION AND USE
ATE99296T1 (en) QUINOXALINE COMPOUNDS AND THEIR PREPARATION AND USE.
ES2034221T3 (en) ANTI-ALLERGIC AND ANTI-INFLAMMATORY AGENTS OF DIHYDROPYRIDINE.
PE58899A1 (en) ESTERS AND AMIDES OF PHENYL XANTINA
HUP9700595A1 (en) Fluoro-alkyl- and fluoro-alkoxy-substituted heterocyclic bradiquinine-antagonists, process for producing them and their use
MEP26608A (en) Aminothiazole derivatives and their use as crf receptor ligands
PE10599A1 (en) PIPERAZINE DERIVATIVES AS NEUROQUININE ANTAGONISTS
PE20040668A1 (en) NEW PIPERIDINE DERIVATIVES

Legal Events

Date Code Title Description
FC Refusal